Takasawa Kazuya, Tomosugi Naohisa, Takaeda Chikako, Maeda Teiryo, Ueda Norishi
Division of Nephrology, Department of Internal Medicine, Public Central Hospital of Matto Ishikawa, Japan.
Division of Advanced Medicine, Medical Research Institute, Kanazawa Medical University, Ishikawa, Japan.
Nephron Extra. 2014 Apr 16;4(1):55-63. doi: 10.1159/000362212. eCollection 2014 Jan.
BACKGROUND/AIMS: We examined whether regulation of hepcidin-25 by short- or long-acting recombinant human erythropoietin (rhEPO) is dependent on ferritin and predicts the response to rhEPO in hemodialysis (HD) patients.
Two studies with rhEPO were performed in 9 HD patients with a 2-year interval. Serum hepcidin-25 was measured at 0-18 h after intravenous epoetin-β (EPO) or methoxy polyethylene glycol-epoetin-β (PEG-EPO) administration and on days 3-7 after PEG-EPO. Hemoglobin (Hb), serum ferritin, transferrin, C-reactive protein (CRP), and interleukin (IL)-6 were analyzed before hepcidin measurement and 6 months after rhEPO. Based on the serum ferritin levels before hepcidin measurement, the patients in the two studies with EPO or PEG-EPO were combined into low (11; serum ferritin of <15.0 ng/ml) and high ferritin groups (7; serum ferritin of ≥15.0 ng/ml). The response of hepcidin-25 to rhEPO and the effect of rhEPO on anemia were compared between the groups.
The serum hepcidin-25 levels rose at 6-9 h and returned to the baseline at 18 h after EPO. They rose at 6-9 h, returned to the baseline at 18 h, and decreased on day 5-7 after PEG-EPO. Serum hepcidin-25 levels were low (<5.0 ng/ml) in the low ferritin group, but rose at 6-9 h after rhEPO in the high ferritin group. Serum transferrin levels were similar, and CRP and IL-6 were normal in both groups. Hb tended to increase in the low ferritin group, but it significantly decreased in the high ferritin group after rhEPO.
Regulation of hepcidin-25 by rhEPO may be dependent on ferritin, affecting the response to rhEPO in HD patients.
背景/目的:我们研究了短效或长效重组人促红细胞生成素(rhEPO)对铁调素-25的调节是否依赖于铁蛋白,并预测血液透析(HD)患者对rhEPO的反应。
对9例HD患者进行了两项间隔2年的rhEPO研究。在静脉注射依泊汀-β(EPO)或甲氧基聚乙二醇-依泊汀-β(PEG-EPO)后0至18小时以及PEG-EPO给药后第3至7天测量血清铁调素-25。在测量铁调素之前以及rhEPO治疗6个月后分析血红蛋白(Hb)、血清铁蛋白、转铁蛋白、C反应蛋白(CRP)和白细胞介素(IL)-6。根据测量铁调素之前的血清铁蛋白水平,将两项使用EPO或PEG-EPO研究中的患者合并为低铁蛋白组(11例;血清铁蛋白<15.0 ng/ml)和高铁蛋白组(7例;血清铁蛋白≥15.0 ng/ml)。比较两组中铁调素-25对rhEPO的反应以及rhEPO对贫血的影响。
EPO给药后,血清铁调素-25水平在6至9小时升高,并在18小时恢复至基线水平。它们在6至9小时升高,在18小时恢复至基线水平,并在PEG-EPO给药后第5至7天下降。低铁蛋白组血清铁调素-25水平较低(<5.0 ng/ml),但高铁蛋白组在rhEPO给药后6至9小时升高。两组血清转铁蛋白水平相似,CRP和IL-6均正常。低铁蛋白组Hb有升高趋势,但rhEPO治疗后高铁蛋白组Hb显著下降。
rhEPO对铁调素-25的调节可能依赖于铁蛋白,影响HD患者对rhEPO的反应。